Drug Trial Radar · NCT06285916
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Mar 28, 2024
Primary completion
Sep 11, 2025
Study completion Oct 6, 2025
Sponsor
- Lead sponsor
- TWi Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD). The trial aims to determine: * How well NORA520 is tolerated and what side effects it may cause * If NORA520 reduces depressive symptoms in subjects with severe PPD * The amount of NORA520 in the blood at various times after taking the study drug; this provides information that helps determine how often NORA520 should be taken * In a subset of subjects, the amount of NORA520 in breastmilk at various times after taking it to determine if and how much NORA520 can pass into breastmilk Participate in this study will be randomly assigned to one of 3 different groups. All subjects will take the study drug for 3 days.
Conditions
- Depression, Postpartum
- Postpartum Depression
- Post-partum Depression
- Postnatal Depression
- Post-Natal Depression
Interventions
NORA520 Dose 1Drug
Oral NORA520 tablets Dose 1 for 3 days
NORA520 Dose 2Drug
Oral NORA520 tablets Dose 2 for 3 days
PlaceboDrug
Oral Placebo tablets for 3 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity, and causality of AEs, SAEs, and AESIsTime frame: Up to Day 30
- Change from baseline in HAM-D17 total score compared to placeboTime frame: Baseline to Day 4
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Pillar Clinical Research
Bentonville, Arkansas
Advanced Research Center
Anaheim, California
Alliance Research Institute
Canoga Park, California
Cenexel Clinical Research
Sherman Oaks, California
Cenexel Clinical Research
Torrance, California
MedOne Clinical Research
Miami, Florida
Meridian International Research, Inc.
Miami Gardens, Florida
Combined Research
Orlando, Florida
Clinical Research Center of Florida
Pompano Beach, Florida
GCP Research
St. Petersburg, Florida
Cenexel Clinical Research
Atlanta, Georgia
CenExel Clinical Research
Decatur, Georgia
CenExel Clinical Research
Savannah, Georgia
Insight Hospital and Medical Center Chicago
Chicago, Illinois
Zucker Hillside Hospital
Glen Oaks, New York
Monroe Biomedical Research
Monroe, North Carolina
Maximos Ob/Gyn
League City, Texas
Pillar Clinical Researc
Richardson, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.